Freeox Biotech, S.L.

We develop medicines addressed to reduce the effects of the oxidative stress in the organism


Carlos Lurigados Delgado (See Profile)




Development, market readiness, clinical trial



Phase IIb clinical Trial with 420 patients with stroke finished

Therapy improves the outcomes of specific populations of stroke patients

Strategic agreements with international companies already done

International team with complementary profiles and strong background in science and business

We have the possibility to commercialise the first drug with demonstrated neuroprotective properties in stroke; a clear unmet medical need

This information is confidential, do not share or copy.

Under evaluation at least till 15th May 2018.

If you want to have more information or you want to review the project, you have to login or register


©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

Aviso de cookies

Log in with your credentials


Forgot your details?

Create Account

Skip to toolbar